Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1975 1
1978 2
1983 1
1985 1
1986 1
1990 2
1993 2
1995 1
1996 2
1998 4
1999 3
2000 7
2001 4
2002 11
2003 11
2004 10
2005 16
2006 12
2007 20
2008 20
2009 31
2010 21
2011 28
2012 33
2013 38
2014 45
2015 38
2016 54
2017 47
2018 43
2019 47
2020 57
2021 60
2022 43
2023 51
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

685 results

Results by year

Filters applied: . Clear all
Page 1
Product review on the IMD serogroup B vaccine Bexsero.
Deghmane AE, Taha MK. Deghmane AE, et al. Hum Vaccin Immunother. 2022 Dec 31;18(1):2020043. doi: 10.1080/21645515.2021.2020043. Epub 2022 Feb 22. Hum Vaccin Immunother. 2022. PMID: 35192786 Free PMC article.
Bexsero is a multicomponent vaccine composed of four major proteins of Neisseria meningitidis: the fHbp, NHBA, NadA and PorA. This vaccine was licensed against invasive meningococcal disease (IMD) due to serogroup B isolates. ...Although the vaccine does not seem to …
Bexsero is a multicomponent vaccine composed of four major proteins of Neisseria meningitidis: the fHbp, NHBA, NadA and PorA. This va …
Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review.
Kassianos G, Barasheed O, Abbing-Karahagopian V, Khalaf M, Ozturk S, Banzhoff A, Badur S. Kassianos G, et al. Infect Dis Ther. 2023 Sep;12(9):2193-2219. doi: 10.1007/s40121-023-00836-8. Epub 2023 Jul 6. Infect Dis Ther. 2023. PMID: 37428339 Free PMC article. Review.
Recombinant vaccines against invasive meningococcal disease due to Neisseria meningitidis serogroup B (MenB) have shown substantial impact in reducing MenB disease in targeted populations. 4CMenB targets four key N. meningitidis protein antigens; human factor H binding pro …
Recombinant vaccines against invasive meningococcal disease due to Neisseria meningitidis serogroup B (MenB) have shown substantial i …
Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine.
Fagnocchi L, Biolchi A, Ferlicca F, Boccadifuoco G, Brunelli B, Brier S, Norais N, Chiarot E, Bensi G, Kroll JS, Pizza M, Donnelly J, Giuliani MM, Delany I. Fagnocchi L, et al. Infect Immun. 2013 Feb;81(2):560-9. doi: 10.1128/IAI.01085-12. Epub 2012 Dec 10. Infect Immun. 2013. PMID: 23230289 Free PMC article.
The NadA adhesin is a major component of 4CMenB, a novel vaccine to prevent meningococcus serogroup B (MenB) infection. ...Our results suggest that during infectious disease, NadR repression is alleviated due to niche-specific signals, resulting in high levels of …
The NadA adhesin is a major component of 4CMenB, a novel vaccine to prevent meningococcus serogroup B (MenB) infection. ...Our …
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.
Lucidarme J, Comanducci M, Findlow J, Gray SJ, Kaczmarski EB, Guiver M, Vallely PJ, Oster P, Pizza M, Bambini S, Muzzi A, Borrow R. Lucidarme J, et al. Clin Vaccine Immunol. 2010 Jun;17(6):919-29. doi: 10.1128/CVI.00027-10. Epub 2010 Apr 7. Clin Vaccine Immunol. 2010. PMID: 20375242 Free PMC article.
Invasive disease caused by meningococcal capsular groups A, C, W-135, and Y is now preventable by means of glycoconjugate vaccines that target their respective polysaccharide capsules. The capsule of group B meningococci (MenB) is poorly immunogenic and may induce autoimmu …
Invasive disease caused by meningococcal capsular groups A, C, W-135, and Y is now preventable by means of glycoconjugate vaccines that targ …
The soluble recombinant Neisseria meningitidis adhesin NadA(delta351-405) stimulates human monocytes by binding to extracellular Hsp90.
Cecchini P, Tavano R, Polverino de Laureto P, Franzoso S, Mazzon C, Montanari P, Papini E. Cecchini P, et al. PLoS One. 2011;6(9):e25089. doi: 10.1371/journal.pone.0025089. Epub 2011 Sep 16. PLoS One. 2011. PMID: 21949862 Free PMC article.
The adhesin NadA favors cell adhesion/invasion by hypervirulent Neisseria meningitidis B (MenB). ...Co-stimulation of monocytes with anti-hsp90 antibodies and NadA(delta351-405) determined a stronger but polymixin B insensitive cell activation. ...
The adhesin NadA favors cell adhesion/invasion by hypervirulent Neisseria meningitidis B (MenB). ...Co-stimulation of monocyte …
The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
Masignani V, Pizza M, Moxon ER. Masignani V, et al. Front Immunol. 2019 Apr 16;10:751. doi: 10.3389/fimmu.2019.00751. eCollection 2019. Front Immunol. 2019. PMID: 31040844 Free PMC article. Review.
The complete genome sequence of an isolate of Neisseria meningitidis serogroup B (MenB) was systematically analyzed to identify proteins predicted to be secreted or exported to the outer membrane. ...The resulting multivalent vaccine formulation selected consisted of three …
The complete genome sequence of an isolate of Neisseria meningitidis serogroup B (MenB) was systematically analyzed to identify prote …
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.
O'Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. O'Ryan M, et al. Drugs. 2014 Jan;74(1):15-30. doi: 10.1007/s40265-013-0155-7. Drugs. 2014. PMID: 24338083 Free PMC article. Review.
Recently approved in Europe and Australia, the multi-component meningococcal B vaccine, 4CMenB (Bexsero, Novartis Vaccines and Diagnostics), contains three surface-exposed recombinant proteins (fHbp, NadA, and NHBA) and New Zealand strain outer membrane vesicles (NZ …
Recently approved in Europe and Australia, the multi-component meningococcal B vaccine, 4CMenB (Bexsero, Novartis Vaccines and Diagno …
Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.
Bowe F, Lavelle EC, McNeela EA, Hale C, Clare S, Arico B, Giuliani MM, Rae A, Huett A, Rappuoli R, Dougan G, Mills KH. Bowe F, et al. Infect Immun. 2004 Jul;72(7):4052-60. doi: 10.1128/IAI.72.7.4052-4060.2004. Infect Immun. 2004. PMID: 15213150 Free PMC article.
Conjugated polysaccharide vaccines protect against serogroup C meningococci. However, this approach cannot be applied to serogroup B, which is still a major cause of meningitis. We evaluated the immunogenicity of three surface-exposed proteins from serogroup B Neiss …
Conjugated polysaccharide vaccines protect against serogroup C meningococci. However, this approach cannot be applied to serogroup B, …
Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil.
Fukasawa LO, Gorla MCO, Lemos APS, Schenkman RPF, Brandileone MCC, Fox JW, Raw I, Frasch CE, Tanizaki MM. Fukasawa LO, et al. J Med Microbiol. 2003 Feb;52(Pt 2):121-125. doi: 10.1099/jmm.0.05017-0. J Med Microbiol. 2003. PMID: 12543917
A mAb against the NadA protein from Neisseria meningitidis strain 3006 (serosubtype B : 2b : P1.2 : P5.2,8) demonstrated strong bactericidal activity against Brazilian epidemic serogroup B strain N44/89 (B : 4,7 : P1.19,15 : P5.5,7) and a serogroup C s …
A mAb against the NadA protein from Neisseria meningitidis strain 3006 (serosubtype B : 2b : P1.2 : P5.2,8) demonstrated stron …
Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection.
González-Miró M, Rodríguez-Noda LM, Fariñas-Medina M, Cedré-Marrero B, Madariaga-Zarza S, Zayas-Vignier C, Hernández-Cedeño M, Kleffmann T, García-Rivera D, Vérez-Bencomo V, Rehm BHA. González-Miró M, et al. Sci Rep. 2018 Jan 30;8(1):1888. doi: 10.1038/s41598-018-20205-7. Sci Rep. 2018. PMID: 29382864 Free PMC article.
An endotoxin-free mutant of Escherichia coli was engineered to produce translational fusions of antigens (Neisseria adhesin A (NadA) and factor H binding protein (fHbp) derived from serogroup B) to the polyhydroxybutyrate synthase (PhaC), in order to intracellularly …
An endotoxin-free mutant of Escherichia coli was engineered to produce translational fusions of antigens (Neisseria adhesin A (NadA) …
685 results